New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
12:58 EDTDDXSdiaDexus recent weakness brings attractive entry point, says Ladenburg
Ladenburg says the recent weakness in shares of diaDexus presents an attractive entry point into the name. The firm expects fundamentals of the company's Lp-PLA2 franchise to strengthen over the next 6-12 months and it reiterates a Buy rating on the stock with a $1.75 price target.
News For DDXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
16:47 EDTDDXSdiaDexus receives FDA clearance for PLAC activity test
diaDexus announced that it has received 510(k) clearance from the FDA for its PLAC Test for Lp-PLA2 Activity. This new test is an enzyme assay for the quantitative determination of Lp-PLA2 activity in human plasma and serum. An analysis based on REGARDS, a U.S.-based National Institutes of Health-funded longitudinal study, using a cohort of approximately 4,500 individuals with no prior history of cardiovascular events, demonstrated that elevated Lp-PLA2 Activity levels are associated with a significant increase for risk of coronary heart disease. To commercialize this new test, diaDexus will use its established salesforce. Beginning in 1Q15, the company expects to start contracting and enabling new lab customers.
15:10 EDTDDXSFDA clears diaDexus screening test for coronary heart disease risk
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use